Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial
Authors:
- 1 August 2004
- journal article
- clinical trial
- Published by Elsevier in Gastroenterology
- Vol. 127 (2) , 395-402
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysisBMJ, 2000
- Nitrovasodilators, Low-Dose Aspirin, Other Nonsteroidal Antiinflammatory Drugs, and the Risk of Upper Gastrointestinal BleedingNew England Journal of Medicine, 2000
- Risk of upper gastrointestinal bleeding associated with use of low-dose aspirinAmerican Journal of Gastroenterology, 2000
- AspirinCirculation, 2000
- Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trialArthritis & Rheumatism, 2000
- A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritisGastroenterology, 1999
- Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered productThe Lancet, 1996
- Prophylactic aspirin and risk of peptic ulcer bleedingBMJ, 1995
- Endoscopic Evaluation of the Effects of Aspirin, Buffered Aspirin, and Enteric-Coated Aspirin on Gastric and Duodenal MucosaNew England Journal of Medicine, 1980